Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
274
Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
University of Göttingen
Göttingen, Lower Saxony, Germany
RECRUITINGEvent free survival
Time frame: 3 years
Rate of complete and partial remissions
Time frame: 4 months after inclusion
treatment related deaths
Time frame: time of occurence
Overall survival
Time frame: @ 3 years
protocol adherence
Time frame: 4 months of treatment
immune reconstitution after alemtuzumab CHOP
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.